Riken Vitamin Co. Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, came to ¥39.14 per share, a decline of 20.3% from ¥49.09 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥865.4 million, a decrease of 20.3% from ¥1.09 billion in the prior-year period.
The normalized profit margin fell to 4.0% from 4.9% in the year-earlier period.
Total revenue declined year over year to ¥21.66 billion from ¥21.94 billion, and total operating expenses came to ¥20.40 billion, compared with ¥20.31 billion in the year-earlier period.
Reported net income totaled ¥1.21 billion, or ¥54.77 per share, compared to ¥1.22 billion, or ¥55.31 per share, in the year-earlier period.
As of Feb. 12, US$1 was equivalent to ¥118.90.
